Regency Centers Corporation (REG)

The 12 engineered components and systems stocks we track reported a strong Q1. As a group, revenues beat analysts’ consensus estimates by 3.8% while next quarter’s revenue guidance was in line. In light of this news, share prices of the companies have held steady. On average, they are relatively unc…

Shares of REG opened at $77.74 on Friday. The stock has a market cap of $14.23 billion, a P/E ratio of 26.81, a price-to-earnings-growth ratio of 3.28 and a beta of 0.82. Regency Centers has a 1 year low of $66.86 and a 1 year high of $81.66. The stock’s 50-day moving average price is $77.61 ...

Range Resources stock gained 9.1% over six months, underperforming the S&P 500. Revenue growth of 9.6% annualized over five years fell short of sector benchmarks, while EBITDA margin declined to 50.5%. Trading at 10.3x forward earnings, analysts see no compelling buying opportunity.

One investment analyst has rated ... to the stock. Based on data from MarketBeat, Regency Centers currently has an average rating of “Hold” and an average target price of $81.71. ... NASDAQ REG opened at $77.74 on Thursday. The company has a market cap of $14.23 billion, a PE ratio of 26.81, a price…

Sie befinden sind hier: Startseite > Börse > Ueberblick > Regeneron Pharma stock (US75886F1075): clinical setback ... ... Regeneron Pharma has been in the spotlight after a Phase 3 trial setback for its cancer candidate fianlimab and recent earnings updates.